Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1

Conditions

Recurrence 2Multiple Myeloma 2Ovarian Neoplasms 1Leukemia, B-Cell 1Leukemia 1Klatskin Tumor 1Fallopian Tube Neoplasms 1Disease Progression 1Disease 1Cholangiocarcinoma 1Breast Neoplasms 1Bile Duct Neoplasms 1

Interventions

Dexamethasone 2vistusertib 1ricolinostat 1pomalidomide 1irinotecan sucrosofate 1idelalisib 1daratumumab 1bermekimab 1atezolizumab 1alovudine 1TKM-080301 1TIC10 compound 1S-Adenosylmethionine 1Prostatectomy 1Pluvicto 1MicroRNAs 1Magnetic Resonance Spectroscopy 1Lenalidomide 1Ipilimumab 1Ga(III)-DOTATOC 1Fluorouracil 1Cyclophosphamide 1Blood Specimen Collection 1(225)Ac-PSMA-617 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Disease × ricolinostat × Clear all
NCT02189343 2019-11-21

Phase 1b Study Evaluating ACY-1215 (Ricolinostat) in Combination With Pomalidomide and Dexamethasone in Relapsed or Relapsed-and-Refractory Multiple Myeloma

Celgene

Phase 1 Completed
16 enrolled
Plasma cell

Disease, Multiple Myeloma, Recurrence, Disease Progression

Data powered by HemOnc (CC BY 4.0) Colophon âš¡